Corient Private Wealth
EDIT icon

Corient Private Wealth’s Editas Medicine EDIT Stock Holding History

Corient Private Wealth’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$79.9K Buy
+24,646
New +$72K ﹤0.01% 2961

Other funds holding EDIT

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Corient Private Wealth's EDIT Position: Q2 2026 in Review

Corient Private Wealth opened a new position in Editas Medicine (EDIT) in Q2 2026: 24,646 shares worth $79.9K. The stake represents ﹤0.01% of the portfolio and ranks #2961 among its holdings.

215 funds tracked by Wall St. Rank hold EDIT as of Q2 2026.

  • Corient Private Wealth held 24,646 shares of Editas Medicine worth $79.9K as of Q2 2026.
  • Editas Medicine was a new Corient Private Wealth position in Q2 2026.
  • Editas Medicine made up ﹤0.01% of Corient Private Wealth's portfolio in Q2 2026, its #2961 holding.
  • 215 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.